Effect of Forsythia suspensa Leaf Tea on with Cirrhosis and Its Mechanism in Rats

doi:10.13560/j.cnki.biotech.bull.1985.2024-0286

Abstract

Abstract:

【Objective】 To study the effects of crude extracts of Forsythia suspensa leaves and their tea solution on carbon tetrachloride（CCl₄）induced liver cirrhosis in rats, and to elucidate the effects and mechanisms of different doses of the crude extracts and tea solution of F. suspensa leaves on gut microbiota diversity. 【Method】 The 30 male SD rats were randomly divided into control group, model group, low, medium, and high-dose F. suspensa leaf tea orally administered group, and tea water group according to the principle of similar average body weight. Liver cirrhosis rat model was constructed by subcutaneous injection of CCl₄+CCl₄ olive oil mixture orally administered group. At the same time, different doses of F. suspensa leaf tea crude extract orally administered, and tea water group were intervened for 10 d. Serum was collected for ELISA detection, liver tissue was stained with HE, the liver tissue RNA was extracted for RT-PCR detection, and fecal samples were subjected to 16S rRNA sequencing. 【Result】 Both the crude extract of F. suspensa leaves and the tea group significantly improved the morphology of liver cirrhosis in rats, especially the tea group significantly reversed the status of liver cirrhosis. Liver cell steatosis, inflammatory cell infiltration around the central vein, and fibrous connective tissue proliferation in the portal area were significantly improved compared to the model group. The crude extract of F. suspensa leaves and the tea group significantly increased the abundance of probiotics Rothia, Paraacteroides, and Lactobacillus, promoting the synthesis of unsaturated fatty acids and the enrichment of acid respiration pathways. The crude extract of F. suspensa leaf tea and the tea group inhibited the levels of DAO, TLR-4, and LPS endotoxin factors in the blood, promoted the expression of anti-inflammatory factor 1L-4 and intestinal barrier function factor ZO-1. The composition of intestinal microbiota among the groups was correlated with DAO, LPS, 1L-4, and TLR4, with the highest correlation with intestinal injury index DAO. 【Conclusion】 The crude extract of F. suspensa leaf tea and tea group inhibit in the pathogenesis of liver cirrhosis by improving the pathological morphology of liver cirrhosis in rats, reducing inflammatory response, improving intestinal microecological dysfunction, and protecting intestinal barrier function.

Key words: Forsythia suspensa leaf tea, liver cirrhosis, diversity of microbes, rat, inflammatory factors, mechanism

WU Yong-na, TENG Wen-long, ZHANG Lei, WANG De-fu, NIU Yan-bing. Effect of Forsythia suspensa Leaf Tea on with Cirrhosis and Its Mechanism in Rats[J]. Biotechnology Bulletin, 2024, 40(11): 285-295.

Figures/Tables 12

Fig. 1 Masson staining of liver between cirrhosis and normal rats A: The rats in the control group had normal liver lobules, no inflammatory infiltration of the central vein, and no connective tissue in the manifold area. B: Rats in the model group had obvious fibrous tissue hyperplasia and pseudolobule formation

Fig. 2 Morphological characteristics of livers in cirrhotic rats Control: Control group. Model: Cirrhosis model group. Tea: Forsythia tea group. Low, Medium and High: 0.5, 0.7 and 1 g/mL crude extract of Forsythia leaf tea, respectively. The same below

Fig. 3 α diversity characteristics of bacterial community in different treatments

Fig. 4 β diversity characteristics among different treatments A: Cluster analysis of β diversity via PLSDA mode. B: Characteristic analysis via the Venn diagram

Fig. 5 Composition and difference of TOP 10 gut bacteria among different treatments at phylum（A）and genus（B）level

Fig. 6 Differential microbiota of gut bacteria among different treatments at genus level

Fig. 7 LefSe analysis of gut bacteria in different treatments

Fig. 8 LAD analysis of gut bacteria in different treatments

Fig. 9 Analysis of differential functional pathways in different treatments A: Metabolic pathways of unsaturated fatty acids. B: Pathways of arabinosaccharide transport system substrate-binding protein. C: Respiratory pathway of fumaric acid. D: β-xylosidase GH43. Different letters indicate significant differences at the P<0.05 level. The same below

Fig. 10 Analysis of inflammatory factor in serum in different treatments 1L-4: Interleukin 4. DAO: Diamine oxidase. LPS: Lipopolysaccharide. TLR4: A member of the toll-like receptor（TLR）family

Fig. 11 Analysis of barrier functional proteins and inflammatory factor in liver tissue in different treatments

Fig. 12 Correlation analysis between intestinal microbes and clinical factors among different treatments A: Spearman correlation analysis between differential microbiota and differential inflammatory factors. B: CCA analysis of differential microbiota and differential inflammatory cytokines

References 40

[1]	Blumberg R, Powrie F. Microbiota, disease, and back to health: a metastable journey[J]. Sci Transl Med, 2012, 4(137): 137rv7.
[2]	Smith MI, Yatsunenko T, Manary MJ, et al. Gut microbiomes of Malawian twin pairs discordant for kwashiorkor[J]. Science, 2013, 339(6119): 548-554.
[3]	Sonnenburg JL, Bäckhed F. Diet-microbiota interactions as moderators of human metabolism[J]. Nature, 2016, 535(7610): 56-64.
[4]	Węgielska I, Suliburska J. The role of intestinal microbiota in the pathogenesis of metabolic diseases[J]. Acta Sci Pol Technol Aliment, 2016, 15(2): 201-211.
[5]	Tilg H. A gut feeling about thrombosis[J]. N Engl J Med, 2016, 374(25): 2494-2496.
[6]	郭慧玲, 邵玉宇, 孟和毕力格, 等. 肠道菌群与疾病关系的研究进展[J]. 微生物学通报, 2015, 42(2): 400-410.
	Guo HL, Shao YY, Menghe B, et al. Research on the relation between gastrointestinal microbiota and disease[J]. Microbiol China, 2015, 42(2): 400-410.
[7]	Claesson MJ, Cusack S, O'Sullivan O, et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly[J]. Proc Natl Acad Sci USA, 2011, 108(Suppl 1): 4586-4591.
[8]	Usami M, Miyoshi M, Yamashita H. Gut microbiota and host metabolism in liver cirrhosis[J]. World J Gastroenterol, 2015, 21(41): 11597-11608.
[9]	Scharlau D, Borowicki A, Habermann N, et al. Mechanisms of primary cancer prevention by butyrate and other products formed during gut flora-mediated fermentation of dietary fibre[J]. Mutat Res, 2009, 682(1): 39-53.
[10]	Wu YN, Zhang L, Chen T, et al. Granulocyte-macrophage colony-stimulating factor protects mice against hepatocellular carcinoma by ameliorating intestinal dysbiosis and attenuating inflammation[J]. World J Gastroenterol, 2020, 26(36): 5420-5436.
[11]	Zhang L, Wu YN, Chen T, et al. Relationship between intestinal microbial dysbiosis and primary liver cancer[J]. Hepatobiliary Pancreat Dis Int, 2019, 18(2): 149-157.
[12]	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[13]	Tao XM, Wang N, Qin WX. Gut microbiota and hepatocellular carcinoma[J]. Gastrointest Tumors, 2015, 2(1): 33-40.
[14]	Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function[J]. Hepatology, 2009, 50(6): 2001-2006.
[15]	冯硕. 中药治疗慢性乙肝病毒携带者、肝纤维化和肝硬化的系统评价及结论偏倚方法学研究[D]. 北京: 北京中医药大学, 2017.
	Feng S. A systematic review of traditional Chinese medicine in the treatment of chronic hepatitis B virus carriers, liver fibrosis and liver cirrhosis, and a methodological study of bias in conclusions[D]. Beijing: Beijing University of Chinese Medicine, 2017.
[16]	梁文欧, 赵力超, 方祥, 等. 大豆异黄酮与肠道微生物相互作用研究进展[J]. 食品科学, 2019, 40(9): 283-289.
	Liang WO, Zhao LC, Fang X, et al. Progress in the research of the interactions of soy isoflavones with gut microbiota[J]. Food Sci, 2019, 40(9): 283-289.
[17]	Li DT, Feng Y, Tian ML, et al. Gut microbiota-derived inosine from dietary barley leaf supplementation attenuates colitis through PPARγ signaling activation[J]. Microbiome, 2021, 9(1): 83.
[18]	曲欢欢, 翟西峰, 李白雪, 等. 连翘不同部位中连翘酯苷和连翘苷的含量分析[J]. 药物分析杂志, 2008, 28(3): 382-385.
	Qu HH, Zhai XF, Li BX, et al. Study of the content of forsythiaside and forsythin from different parts of Forsythia suspensa(Thunb.) Vahl[J]. Chin J Pharm Anal, 2008, 28(3): 382-385.
[19]	张炜, 张汉明, 郭美丽, 等. 连翘的药理学研究[J]. 中国现代应用药学, 2000, 17(1): 7-10.
	Zhang W, Zhang HM, Guo ML, et al. Pharmacological studies of forsythia[J]. Chin J Mod Appl Pharm, 2000, 17(1): 7-10.
[20]	滕文龙, 吴永娜, 王德富, 等. 连翘叶茶对肝癌细胞增殖和迁移功能的影响及其作用机制[J]. 生物技术通报, 2024, 40(4): 287-296.
	Teng WL, Wu YN, Wang DF, et al. Effect of Forsythia suspensa leaves tea on HCC proliferation and migration function and its mechanism of action[J]. Biotechnol Bull, 2024, 40(4): 287-296.
[21]	白美美. 连翘叶茶保肝作用研究[D]. 太原: 山西大学, 2018.
	Bai MM. Study on hepatoprotective effect of Forsythia suspensa leaves tea[D]. Taiyuan: Shanxi University, 2018.
[22]	袁盛榕, 库宝善. 药理学实习教程[M]. 2版. 北京: 世界图书出版公司, 1994: 12-13.
	Yuan SR, Ku BS. Pharmacology Internship Tutorial[M]. 2nd ed. Beijing: World Publishing Corportion, 1994: 12-13.
[23]	Lin ZS, Wu JM, Wang JP, et al. Dietary Lactobacillus reuteri prevent from inflammation mediated apoptosis of liver via improving intestinal microbiota and bile acid metabolism[J]. Food Chem, 2023, 404(Pt B): 134643.
[24]	Zhao CJ, Bao LJ, Qiu M, et al. Commensal cow Roseburia reduces gut-dysbiosis-induced mastitis through inhibiting bacterial translocation by producing butyrate in mice[J]. Cell Rep, 2022, 41(8): 111681.
[25]	Sang JN, Zhuang DH, Zhang T, et al. Convergent and divergent age patterning of gut microbiota diversity in humans and nonhuman primates[J]. mSystems, 2022, 7(4): e0151221.
[26]	Dai SP, Wang ZL, Yang Y, et al. PM2.5 induced weight loss of mice through altering the intestinal microenvironment: mucus barrier, gut microbiota, and metabolic profiling[J]. J Hazard Mater, 2022, 431: 128653.
[27]	Teng SS, Zhang YF, Jin XH, et al. Structure and hepatoprotective activity of Usp10/NF-κB/Nrf2 pathway-related Morchella esculenta polysaccharide[J]. Carbohydr Polym, 2023, 303: 120453.
[28]	Spinelli JB, Rosen PC, Sprenger HG, et al. Fumarate is a terminal electron acceptor in the mammalian electron transport chain[J]. Science, 2021, 374(6572): 1227-1237.
[29]	Zecchini V, Paupe V, Herranz-Montoya I, et al. Fumarate induces vesicular release of mtDNA to drive innate immunity[J]. Nature, 2023, 615(7952): 499-506.
[30]	Schubert K, Olde Damink SWM, von Bergen M, et al. Interactions between bile salts, gut microbiota, and hepatic innate immunity[J]. Immunol Rev, 2017, 279(1): 23-35.
[31]	Guo Z, Zhang JC, Wang ZL, et al. Intestinal microbiota distinguish gout patients from healthy humans[J]. Sci Rep, 2016, 6: 20602.
[32]	Atarashi K, Nishimura J, Shima T, et al. ATP drives lamina propria T_H17 cell differentiation[J]. Nature, 2008, 455(7214): 808-812.
[33]	Abu-Shanab A, Quigley EMM. The role of the gut microbiota in nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol, 2010, 7(12): 691-701.
[34]	Ye JZ, Lv LX, Wu WR, et al. Butyrate protects mice against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis by improving gut barrier function, attenuating inflammation and reducing endotoxin levels[J]. Front Microbiol, 2018, 9: 1967.
[35]	Sun SS, Wang K, Ma K, et al. An insoluble polysaccharide from the sclerotium of Poria cocos improves hyperglycemia, hyperlipidemia and hepatic steatosis in ob/ob mice via modulation of gut microbiota[J]. Chin J Nat Med, 2019, 17(1): 3-14.
[36]	Gadde U, Oh ST, Lee YS, et al. The effects of direct-fed microbial supplementation, as an alternative to antibiotics, on growth performance, intestinal immune status, and epithelial barrier gene expression in broiler chickens[J]. Probiotics Antimicrob Proteins, 2017, 9(4): 397-405.
[37]	Mridha AR, Wree A, Robertson AAB, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice[J]. J Hepatol, 2017, 66(5): 1037-1046.
[38]	姜冰. 肝硬化患者DAO、内毒素、D-乳酸变化及在肠黏膜屏障功能评估中的作用[J]. 中国实用医药, 2017, 12(33): 33-34.
	Jiang B. Changes in DAO, endotoxin, D-lactate and intestinal mucosa in patients with cirrhosis role in the assessment of barrier function[J]. China Pract Med, 2017, 12(33): 33-34.
[39]	王海娟, 戴雨珂, 潘渠. 魏斯氏菌的研究现状[J]. 成都医学院学报, 2014, 9(6): 747-750.
	Wang HJ, Dai YK, Pan Q. Current status of Weissella research[J]. J Chengdu Med Coll, 2014, 9(6): 747-750.
[40]	克里斯·韦伯. 长寿密码: 来自科学前沿的健康长寿秘诀[M]. 王钊, 范丽, 译. 北京: 科学出版社, 2019.
	Verburgh K. The longevity code: secrets to living well for longer from the front lines of science[M]. Wang Z, Fan L, translated. Beijing: Science Press, 2019.